



Rx FOR SUCCESS

Skin Cancer

Skin cancer is the most common form of human cancer. The most common cause of skin cancer is overexposure to the sun. Ninety percent of all skin cancers occur on sun exposed skin. People most likely to get skin cancer have:

- ▶ A family history of melanoma
- ▶ Fair skin which burns easily and tans poorly
- ▶ Red or blonde hair
- ▶ Blistering sunburns in childhood or adolescence
- ▶ Dysplastic nevi (atypical moles)

There are three types of skin cancer: basal cell carcinoma, squamous cell carcinoma, and malignant melanoma.

Basal cell carcinoma is the most common type and has the best prognosis. It usually looks like a small pearly nodule that slowly grows. Lesions are surgically removed. Recurrences are common, but it rarely metastasizes (spreads to distant sites). Localized basal cell cancers, after excision, are non-rated.

Squamous cell carcinoma can be a nodule or a reddish patch. Recurrences are also common and 3% – 10% will metastasize. Localized squamous cell cancers, after excision, are non-rated.

Malignant melanoma is the least common, but most serious and can start as a mole. Lesions are surgically removed. Melanoma metastasizes early and widely. Even after surgical removal, recurrences can occur. Prognostic factors include lesion thickness, Clark's level of invasion, growth pattern, skin ulceration (the superficial loss of tissue on the surface of the skin or lesion), number of melanomas, number and size of positive nodes, intralymphatic metastases, and distant metastases.

The staging system for cutaneous (skin) melanoma puts emphasis on ulceration (as reported in the pathology or surgeon's report) and on information obtained from new technology that can detect minute lymphatic metastases. Staging is based on the TNM (Tumor, node, metastasis) classification, and ratings are based on the TNM staging system, specifically tumor characteristics (aka T1a, T1b, T2a, etc).

Applicants with positive lymph nodes or metastases are not insurable.

This material is designed to provide general information about the subject matter covered. It should be used with the understanding that we are not rendering legal, accounting, or tax advice. Such services should be provided by the client's professional advisors. Accordingly, any information in this document cannot be used by any taxpayer for purposes of avoiding penalties under the Internal Revenue Code.

This material is intended for insurance informational purposes only and is not personal medical advice for clients. Rates and availability will vary based on the satisfaction of our underwriting criteria. Underwriting rules are subject to change at our discretion. This marketing material is subject to an expiration date, and use of this material must be discontinued as of the expiration date.

Insurance issued by The Prudential Insurance Company of America and its affiliates, Newark, NJ.

NOT FOR CONSUMER USE.

© 2012 Prudential Financial, Inc. and its related entities.
0192219-00002-00 Ed. 01/2013 Exp. 01/02/2015 Rx 032

Securities and Insurance Products:

Not Insured by FDIC or Any Federal Government Agency.
May Lose Value.

Not a Deposit of or Guaranteed by Any Bank or Bank Affiliate.



Prudential
Bring Your Challenges[®]

The rating for malignant melanoma ranges from no rating for in-situ cancers to postpone for 4 years for Clark levels IV and V.

TUMOR – ALL CRITERIA MUST FIT	THICKNESS	CLARK’S LEVEL	ULCERATION
Tis	<=1.0mm	Level I in-situ	NA
T1a	<=1.0mm	Clark’s level II or III	No
T1b	<=1.0mm	Clark’s level II or III	Yes
T1b	<=1.0mm	Clark’s level IV or V	Yes/No
T2a	1.01 to 2.0mm	NA	No
T2b	1.01 to 2.0mm	NA	Yes
T3a	2.01 to 4.0mm	NA	No
T3b	2.01 to 4.0mm	NA	Yes
T4a	>4.0mm	NA	No
T4b	>4.0mm	NA	Yes

TUMOR	TIS	T1A	T1B	T2A	T2B	T3A	T3B, T4A
1st yr	0	0	\$7.50x5	\$7.50x6	\$10x6	R	R
2nd yr	0	0	\$7.50x4	\$7.50x5	\$10x5	R	R
3rd yr	0	0	\$7.50x3	\$7.50x4	\$10x4	R	R
4th yr	0	0	\$7.50x2	\$7.50x3	\$10x3	R	R
5th yr	0	0	\$7.50x1	\$7.50x2	\$10x2	\$15x6	R
6th yr	0	0	0	\$7.50x1	\$10x1	\$15x5	\$20x5
7th yr	0	0	0	0	0	\$15x4	\$20x4
8th yr	0	0	0	0	0	\$15x3	\$20x3
9th yr	0	0	0	0	0	\$15x2	\$20x2
10th yr	0	0	0	0	0	\$15x1	\$20x1
After 10yr	0	0	0	0	0	0	0

▶ Only Tis through T4a will be considered in underwriting. There must be no evidence of distant or node metastases. Satellite lesions and lesions-in-transit (i.e. within the lymph channels) are considered metastatic.

▶ Recurrent melanomas are declined.

To get an idea of how a client with a history of skin cancer would be viewed in the underwriting process, use the Ask “Rx”pert Underwriter on the next page for an informal quote.

Ask "Rx"pert Underwriter (Ask Our Expert)

After reading the *Rx for Success* on Skin Cancer, use this form to Ask "Rx"pert Underwriter for an informal quote.

Producer _____ Phone _____ Fax _____
 Client _____ Age/DOB _____ Sex _____

If your client has had skin cancer, please answer the following:

1. Please list date of first diagnosis.

2. Please indicate the number of episodes and date of last episode.

- Basal cell carcinoma
 Squamous cell carcinoma
 Malignant melanoma

3. Please note where the skin cancer was located.

4. Has the cancer metastasized (spread) beyond the skin?

- Yes. Please give details. _____
 No

5. Has there been any evidence of recurrence?

- Yes. Please give details. _____
 No

6. For malignant melanoma only. Please provide all items.

- Stage if available
 Ulcerated Yes _____ No _____
 Clark's Level _____
 Thickness in mm _____
 Any positive Lymph Node Yes _____ No _____

7. Is your client on any medications?

- Yes. Please give details. _____
 No

8. Does your client have any other major health problems (e.g., heart disease, etc)?

- Yes. Please give details. _____
 No